Cancer blood test advances toward FDA approval after Mayo research

An FDA advisory panel recommended approval of the Galleri blood test, developed by Grail and researched by the Mayo Clinic, which detects multiple cancers earlier than current screenings. The test, shown to be 99% effective in ruling out cancer risks within one year, is expected to become FDA-approved, potentially lowering costs and complementing existing cancer screening methods.

This Wire brief sits within Fusion42's coverage of Medtech, and 9 sources have reported it between 23 Sep 2026 and 24 Sep 2026.